메뉴 건너뛰기




Volumn 132, Issue 2, 2013, Pages

Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: An updated meta-analysis of ten randomized controlled trials

Author keywords

advanced gastric cancer; first line; irinotecan; meta analysis

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

EID: 84869492742     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27775     Document Type: Review
Times cited : (14)

References (42)
  • 1
    • 0037138446 scopus 로고    scopus 로고
    • Incidence and mortality from stomach cancer in Japan, Slovenia and the USA
    • Lambert R, Guilloux A, Oshima A, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002; 97: 811-18.
    • (2002) Int J Cancer , vol.97 , pp. 811-818
    • Lambert, R.1    Guilloux, A.2    Oshima, A.3
  • 4
    • 84863343266 scopus 로고    scopus 로고
    • Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010
    • Jing JJ, Liu HY, Hao JK, et al. Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol 2012; 18: 1262-9.
    • (2012) World J Gastroenterol , vol.18 , pp. 1262-1269
    • Jing, J.J.1    Liu, H.Y.2    Hao, J.K.3
  • 5
    • 71349083374 scopus 로고    scopus 로고
    • Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: A population-level analysis of trends and projections
    • Yeh JM, Goldie SJ, Kuntz KM, et al. Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. Cancer Causes Control 2009; 20: 2021-9.
    • (2009) Cancer Causes Control , vol.20 , pp. 2021-2029
    • Yeh, J.M.1    Goldie, S.J.2    Kuntz, K.M.3
  • 6
    • 33745547767 scopus 로고    scopus 로고
    • Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
    • Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-9.
    • (2006) J Clin Oncol , vol.24 , pp. 2903-2909
    • Wagner, A.D.1    Grothe, W.2    Haerting, J.3
  • 7
  • 8
    • 34447255242 scopus 로고    scopus 로고
    • Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: Randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
    • Lutz MP, Wilke H, Wagener DJ, et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007; 25: 2580-5.
    • (2007) J Clin Oncol , vol.25 , pp. 2580-2585
    • Lutz, M.P.1    Wilke, H.2    Wagener, D.J.3
  • 9
    • 34848927813 scopus 로고    scopus 로고
    • Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: Results of a phase II trial
    • Lorenzen S, Hentrich M, Haberl C, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007; 18: 1673-9.
    • (2007) Ann Oncol , vol.18 , pp. 1673-1679
    • Lorenzen, S.1    Hentrich, M.2    Haberl, C.3
  • 10
    • 84858283338 scopus 로고    scopus 로고
    • The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: A single-institution experience
    • Ben Aharon I, Purim O, Kundel Y, et al. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience. Anticancer Drugs 2012; 23: 313-20.
    • (2012) Anticancer Drugs , vol.23 , pp. 313-320
    • Ben Aharon, I.1    Purim, O.2    Kundel, Y.3
  • 11
    • 84859966845 scopus 로고    scopus 로고
    • Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403)
    • Tamura S, Imano M, Takiuchi H, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 2012; 32: 1403-8.
    • (2012) Anticancer Res , vol.32 , pp. 1403-1408
    • Tamura, S.1    Imano, M.2    Takiuchi, H.3
  • 12
    • 84861540507 scopus 로고    scopus 로고
    • Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: Aretrospective analysis of single institution
    • Inal A, Kaplan MA, Kucukoner M, et al. Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: aretrospective analysis of single institution. Neoplasma 2012; 59: 233-6.
    • (2012) Neoplasma , vol.59 , pp. 233-236
    • Inal, A.1    Kaplan, M.A.2    Kucukoner, M.3
  • 13
    • 34548258255 scopus 로고    scopus 로고
    • Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group
    • Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25: 3205-9.
    • (2007) J Clin Oncol , vol.25 , pp. 3205-3209
    • Ajani, J.A.1    Moiseyenko, V.M.2    Tjulandin, S.3
  • 14
    • 0024420685 scopus 로고
    • Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
    • Hsiang YH, Lihou MG, Liu LF,. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
    • (1989) Cancer Res , vol.49 , pp. 5077-5082
    • Hsiang, Y.H.1    Lihou, M.G.2    Liu, L.F.3
  • 15
    • 0028225471 scopus 로고
    • Comparison of topoisomerase i inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
    • Tanizawa A, Fujimori A, Fujimori Y, et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 836-42.
    • (1994) J Natl Cancer Inst , vol.86 , pp. 836-842
    • Tanizawa, A.1    Fujimori, A.2    Fujimori, Y.3
  • 16
    • 0028276113 scopus 로고
    • CPT-11 Gastrointestinal Cancer Study Group
    • Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer
    • Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994; 21: 1033-8.
    • (1994) Gan to Kagaku Ryoho , vol.21 , pp. 1033-1038
    • Futatsuki, K.1    Wakui, A.2    Nakao, I.3
  • 17
    • 0141887353 scopus 로고    scopus 로고
    • Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentric trial
    • Kohne CH, Catane R, Klein B, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003; 89: 997-1001.
    • (2003) Br J Cancer , vol.89 , pp. 997-1001
    • Kohne, C.H.1    Catane, R.2    Klein, B.3
  • 18
    • 30844449923 scopus 로고    scopus 로고
    • A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    • Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005; 50: 2218-23.
    • (2005) Dig Dis Sci , vol.50 , pp. 2218-2223
    • Enzinger, P.C.1    Kulke, M.H.2    Clark, J.W.3
  • 19
    • 22344456355 scopus 로고    scopus 로고
    • Irinotecan plus cisplatin combination against metastatic gastric cancer: Phase II study
    • Altinbas M, Er O, Ozkan M, et al. Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study. Med Oncol 2005; 22: 153-60.
    • (2005) Med Oncol , vol.22 , pp. 153-160
    • Altinbas, M.1    Er, O.2    Ozkan, M.3
  • 20
    • 0032919992 scopus 로고    scopus 로고
    • Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
    • Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-23.
    • (1999) J Clin Oncol , vol.17 , pp. 319-323
    • Boku, N.1    Ohtsu, A.2    Shimada, Y.3
  • 21
    • 78650620190 scopus 로고    scopus 로고
    • Irinotecan-involved regimens for advanced gastric cancer: A pooled-analysis of clinical trials
    • Wang DL, Gu DY, Huang HY, et al. Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials. World J Gastroenterol 2010; 16: 5889-94.
    • (2010) World J Gastroenterol , vol.16 , pp. 5889-5894
    • Wang, D.L.1    Gu, D.Y.2    Huang, H.Y.3
  • 22
    • 71249128928 scopus 로고    scopus 로고
    • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study
    • Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet 2009; 10: 1063-9.
    • (2009) Lancet , vol.10 , pp. 1063-1069
    • Boku, N.1    Yamamoto, S.2    Fukuda, H.3
  • 23
    • 79958270201 scopus 로고    scopus 로고
    • Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
    • Komatsu Y, Takahashi Y, Kimura Y, et al. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). Anticancer Drugs 2011; 22: 576-83.
    • (2011) Anticancer Drugs , vol.22 , pp. 576-583
    • Komatsu, Y.1    Takahashi, Y.2    Kimura, Y.3
  • 24
    • 79953025190 scopus 로고    scopus 로고
    • Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
    • Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011; 14: 72-80.
    • (2011) Gastric Cancer , vol.14 , pp. 72-80
    • Narahara, H.1    Iishi, H.2    Imamura, H.3
  • 25
    • 0242356584 scopus 로고    scopus 로고
    • Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC)
    • .: Abstract
    • Hawkins R, Cunningham D, Soerbye H, et al. Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 2003; 22: Abstract 1032.
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 1032
    • Hawkins, R.1    Cunningham, D.2    Soerbye, H.3
  • 26
    • 84871096142 scopus 로고    scopus 로고
    • FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study
    • .: Abstract
    • Glenjen N, Hammerling K, Hatlevoll L, et al. FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: a randomized phase II study. J Clin Oncol 2012; 30: Abstract 71.
    • (2012) J Clin Oncol , vol.30 , pp. 71
    • Glenjen, N.1    Hammerling, K.2    Hatlevoll, L.3
  • 27
    • 84864350608 scopus 로고    scopus 로고
    • Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report
    • .: Abstract
    • Kishimoto T, Imamura H, Uedou F, et al. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): final report. J Clin Oncol 2010; 28: Abstract 4015.
    • (2010) J Clin Oncol , vol.28 , pp. 4015
    • Kishimoto, T.1    Imamura, H.2    Uedou, F.3
  • 28
    • 77953464230 scopus 로고    scopus 로고
    • A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer
    • .: Abstract
    • Boukovinas I, Androulakis N, Polyzos A, et al. A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer. J Clin Oncol 2009; 27: Abstract 4536.
    • (2009) J Clin Oncol , vol.27 , pp. 4536
    • Boukovinas, I.1    Androulakis, N.2    Polyzos, A.3
  • 29
    • 0032558314 scopus 로고    scopus 로고
    • Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?
    • Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
    • (1998) Lancet , vol.352 , pp. 609-613
    • Moher, D.1    Pham, B.2    Jones, A.3
  • 30
    • 0032583387 scopus 로고    scopus 로고
    • Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
    • Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34.
    • (1998) Stat Med , vol.17 , pp. 2815-2834
    • Parmar, M.K.1    Torri, V.2    Stewart, L.3
  • 31
    • 12744274510 scopus 로고    scopus 로고
    • Heterogeneity testing in meta-analysis of genome searches
    • Zintzaras E, Ioannidis JP,. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28: 123-37.
    • (2005) Genet Epidemiol , vol.28 , pp. 123-137
    • Zintzaras, E.1    Ioannidis, J.P.2
  • 32
    • 0021909115 scopus 로고
    • β-Blockade during and after myocardial infarction: An overview of the randomized trials
    • Yusuf S, Peto R, Lewis J, et al. β-Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
    • (1985) Prog Cardiovasc Dis , vol.27 , pp. 335-371
    • Yusuf, S.1    Peto, R.2    Lewis, J.3
  • 33
    • 0028659004 scopus 로고
    • Operating characteristics of a rank correlation test for publication bias
    • Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
    • (1994) Biometrics , vol.50 , pp. 1088-1101
    • Begg, C.B.1    Mazumdar, M.2
  • 34
    • 0032430986 scopus 로고    scopus 로고
    • Power and sample size calculations for studies involving linear regression
    • Dupont WD, Plummer WD, Jr,. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19: 589-601.
    • (1998) Control Clin Trials , vol.19 , pp. 589-601
    • Dupont, W.D.1    Plummer, Jr.W.D.2
  • 35
    • 48849094297 scopus 로고    scopus 로고
    • Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
    • Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-7.
    • (2008) Ann Oncol , vol.19 , pp. 1450-1457
    • Dank, M.1    Zaluski, J.2    Barone, C.3
  • 36
    • 77949326012 scopus 로고    scopus 로고
    • A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
    • Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010; 21: 71-7.
    • (2010) Ann Oncol , vol.21 , pp. 71-77
    • Moehler, M.1    Kanzler, S.2    Geissler, M.3
  • 37
    • 13244266683 scopus 로고    scopus 로고
    • Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803
    • Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-28.
    • (2004) J Clin Oncol , vol.22 , pp. 4319-4328
    • Bouche, O.1    Raoul, J.L.2    Bonnetain, F.3
  • 38
    • 22144469838 scopus 로고    scopus 로고
    • Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
    • Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-8.
    • (2005) Br J Cancer , vol.92 , pp. 2122-2128
    • Moehler, M.1    Eimermacher, A.2    Siebler, J.3
  • 39
    • 57249084776 scopus 로고    scopus 로고
    • Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution
    • Nakashima K, Hironaka S, Boku N, et al. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution. Jpn J Clin Oncol 2008; 38: 810-15.
    • (2008) Jpn J Clin Oncol , vol.38 , pp. 810-815
    • Nakashima, K.1    Hironaka, S.2    Boku, N.3
  • 40
    • 79959631111 scopus 로고    scopus 로고
    • Residual embryonic cells as precursors of a Barrett's-like metaplasia
    • Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 2011; 145: 1023-35.
    • (2011) Cell , vol.145 , pp. 1023-1035
    • Wang, X.1    Ouyang, H.2    Yamamoto, Y.3
  • 41
    • 84865123975 scopus 로고    scopus 로고
    • Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer
    • Reim D, Gertler R, Novotny A, et al. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol 2012; 19: 2108-18.
    • (2012) Ann Surg Oncol , vol.19 , pp. 2108-2118
    • Reim, D.1    Gertler, R.2    Novotny, A.3
  • 42
    • 77950860026 scopus 로고    scopus 로고
    • Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram
    • Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010; 251: 640-6.
    • (2010) Ann Surg , vol.251 , pp. 640-646
    • Strong, V.E.1    Song, K.Y.2    Park, C.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.